Consistent with this, recent studies have shown that inhibition of HSP90 can reduce cardiac hypertrophy by inhibiting the RIP1–RIP3–MLKL pathway, thereby improving therapeutic efficacy [149]. The gene discussed is HSP90AA1; the disease is cardiac hypertrophy.